+

WO2002066477A3 - Imidazopyridines - Google Patents

Imidazopyridines Download PDF

Info

Publication number
WO2002066477A3
WO2002066477A3 PCT/GB2002/000634 GB0200634W WO02066477A3 WO 2002066477 A3 WO2002066477 A3 WO 2002066477A3 GB 0200634 W GB0200634 W GB 0200634W WO 02066477 A3 WO02066477 A3 WO 02066477A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compound
relates
present
imidazopyridines
Prior art date
Application number
PCT/GB2002/000634
Other languages
French (fr)
Other versions
WO2002066477A2 (en
Inventor
Alexander Graham Dossetter
Peter Kenny
Darren Mckerrecher
Michael Wardleworth
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Alexander Graham Dossetter
Peter Kenny
Darren Mckerrecher
Michael Wardleworth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Alexander Graham Dossetter, Peter Kenny, Darren Mckerrecher, Michael Wardleworth filed Critical Astrazeneca Ab
Priority to AU2002229976A priority Critical patent/AU2002229976A1/en
Publication of WO2002066477A2 publication Critical patent/WO2002066477A2/en
Publication of WO2002066477A3 publication Critical patent/WO2002066477A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds wherein: - R1, R2 and R3 are as defined in the description; and ring A is optionally further substituted.
PCT/GB2002/000634 2001-02-20 2002-02-15 Imidazopyridines WO2002066477A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002229976A AU2002229976A1 (en) 2001-02-20 2002-02-15 Imidazopyridines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100567-7 2001-02-20
SE0100567A SE0100567D0 (en) 2001-02-20 2001-02-20 Compounds

Publications (2)

Publication Number Publication Date
WO2002066477A2 WO2002066477A2 (en) 2002-08-29
WO2002066477A3 true WO2002066477A3 (en) 2002-10-17

Family

ID=20283057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000634 WO2002066477A2 (en) 2001-02-20 2002-02-15 Imidazopyridines

Country Status (3)

Country Link
AU (1) AU2002229976A1 (en)
SE (1) SE0100567D0 (en)
WO (1) WO2002066477A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10246890A1 (en) * 2002-10-08 2004-04-22 Grünenthal GmbH New C-(imidazo-(1,2-a)-pyridin-3-yl)-methylamines, are nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, septic shock, neurodegenerative diseases, inflammatory pain or cancer
DE10247271A1 (en) * 2002-10-10 2004-08-26 Grünenthal GmbH Use of new and known 7-(methyl or trifluoromethyl)-imidazo-(1,2-a)-pyridines as nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, neurodegenerative diseases, inflammatory pain, diabetes or cancer
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7723324B2 (en) 2003-10-28 2010-05-25 Sepracor, Inc. Imidazo[1,2-A]pyridine anxiolytics
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275182A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
WO2007069565A1 (en) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
AU2007233709A1 (en) * 2006-03-31 2007-10-11 Novartis Ag Organic compounds
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
EP2070927A4 (en) * 2006-09-13 2010-10-13 Kyowa Hakko Kirin Co Ltd Fused heterocyclic derivative
MX2009006706A (en) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Bicyclic heterocyclic compounds as fgfr inhibitors.
JP5442449B2 (en) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド New compounds
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP2137184B1 (en) 2007-04-03 2013-05-08 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
EP2213672A4 (en) * 2007-10-24 2012-05-02 Nihon Mediphysics Co Ltd NOVEL COMPOUND HAVING AFFINITY TO AN AMYLOID SUBSTANCE
JP5774982B2 (en) * 2008-05-19 2015-09-09 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Imidazo [1,2-a] pyridine compound
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN104619707A (en) 2012-07-31 2015-05-13 协和发酵麒麟株式会社 Condensed ring heterocyclic compound
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
ES2928164T3 (en) 2015-10-19 2022-11-15 Incyte Corp Heterocyclic compounds as immunomodulators
MY199220A (en) 2015-11-19 2023-10-20 Incyte Corp Heterocyclic compounds as immunomodulators
LT3394033T (en) 2015-12-22 2021-03-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US9926316B2 (en) * 2016-03-03 2018-03-27 The Cleveland Clinic Foundation Antitumor derivatives for differentiation therapy
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
ES2905980T3 (en) 2016-05-26 2022-04-12 Incyte Corp Heterocyclic compounds as immunomodulators
MD3472167T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
MX391980B (en) 2016-12-22 2025-03-21 Incyte Corp TETRAHYDROIMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS INDUCERS OF PROGRAMMED DEATH LIGAND 1 (PD-L1) INTERNALIZATION.
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzoxazole derivatives as immunomodulators
LT4212529T (en) 2018-03-30 2025-05-12 Incyte Corporation Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
PE20221038A1 (en) 2019-09-30 2022-06-17 Incyte Corp PYRIDO[3,2-D] PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
TW202120504A (en) 2019-11-11 2021-06-01 美商英塞特公司 Salts and crystalline forms of a pd-1/pd-l1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
CN113666926A (en) * 2021-09-08 2021-11-19 桂林理工大学 A Facile Michal Addition of 2-phenylimidazo[1,2-a]pyridine to Chalcone

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019953A2 (en) * 1995-11-28 1997-06-05 Asta Medica Aktiengesellschaft New lh-rh antagonists with improved effectiveness
WO1998003505A2 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
WO1999041252A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999041251A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019953A2 (en) * 1995-11-28 1997-06-05 Asta Medica Aktiengesellschaft New lh-rh antagonists with improved effectiveness
WO1998003505A2 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
WO1999041252A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999041251A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAMINSKI J J ET AL: "JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 28, no. 7, 1985, pages 876 - 892, XP002094814, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Also Published As

Publication number Publication date
WO2002066477A2 (en) 2002-08-29
SE0100567D0 (en) 2001-02-20
AU2002229976A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
WO2002066477A3 (en) Imidazopyridines
SE0100568D0 (en) Compounds
WO2003082853A8 (en) New compounds
MXPA04005209A (en) ADENOSINE A ??2a? RECEPTOR ANTAGONISTS.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
NZ514574A (en) Novel method of treatment
SE0100566D0 (en) Compounds
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
TW200745111A (en) New compounds
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2002065979A3 (en) (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
MXPA04003192A (en) Succinic acid salts of 5, 8, 14-triazatetracyclo '10.3.1.0 <2,11>.0<4,9> -hexadeca -2(11), 3, 5, 7, 9-pentaene and pharmaceutical compositions thereof.
MXPA04002338A (en) Carbazole derivatives and their use as npy5 receptor antagonists.
MXPA05011076A (en) Chemical compounds.
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2004032826A3 (en) Process for preparing tannate tablet capsule or other solid dosage forms
SE0102440D0 (en) New compound
MXPA04000779A (en) Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease.
WO2003047505A3 (en) Topoisomerase poison agents
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
ATE384066T1 (en) THIENO-PYRROLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN-REleasing HORMONE RECEPTORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载